Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials (Q44428863)

2 December 2017

0 references

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials (English)

1 reference

2 December 2017

0 references

1 reference

Stephen R Marder

1

1 reference

2 December 2017

Robert D McQuade

2

1 reference

2 December 2017

Elyse Stock

3

1 reference

2 December 2017

Stephen Kaplita

4

1 reference

2 December 2017

Ronald Marcus

5

1 reference

2 December 2017

Allan Z Safferman

6

1 reference

2 December 2017

Anutosh Saha

7

1 reference

2 December 2017

Mirza Ali

8

1 reference

2 December 2017

Taro Iwamoto

9

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

2 December 2017

Schizophrenia Research

1 reference

2 December 2017

61

1 reference

2 December 2017

2-3

1 reference

2 December 2017

123-136

1 reference

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

The unhealthy lifestyle of people with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Network interactions in schizophrenia - therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Motor and mental aspects of acute extrapyramidal syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Antipsychotics and the risk of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Dopamine antagonists and the development of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Bodyweight gain with atypical antipsychotics. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

Weight gain: side effect of atypical neuroleptics?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900050-1

7 January 2021

10.1016/S0920-9964(03)00050-1

Identifiers

DOI

1 reference

2 December 2017

1 reference